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of the HTA process in Japan, which is excluded from this analysis. NICE, PBAC and 
the SMC all require the number of patients with the indicated disease and a clear 
statement of patient numbers eligible for treatment per year for 5 years. Beyond 
this, the requirements of the Australian PBC and the SMC were similar, specifying 
prevalence, incidence and mortality data, whereas NICE requires a measure of dis-
ease burden (not clearly defined) and life expectancy among those with the disease. 
The epidemiology requirements did not differ by disease area. ConClusions: HTA 
bodies stipulate the inclusion of epidemiological data to estimate economic impact 
of interventions. Some requirements are common to all agencies, but there are 
also some important differences. Specific epidemiological data needs for individual 
agencies must be considered by drug developers when planning and gathering 
information for HTA submissions.
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objeCtives: To explore the inclusion and evaluation of patient preference data in 
AMNOG early benefit dossiers. Methods: Patient perspective is becoming increas-
ingly important in health care decision making. Health technology assessment (HTA) 
agencies include patient views in their appraisals in different ways and to various 
extents. Patient views and preferences can be captured either by engaging patient 
organisations, patients themselves, or informal carers in the HTA process (as is 
done for example in the UK or Canada). Such patient aspects can be also explored in 
qualitative and quantitative studies which are considered as part of evidence docu-
mentation by the assessment committees. We have reviewed value dossiers and cor-
responding benefit assessments in Germany from 1st January 2011 to 31th March 2014. 
Types of patient preference data included in the value dossiers and their consideration 
in the assessments were collected and summarised. Results: A total of 68 dossiers 
were analyzed. 18 dossiers (26%) included data on patient preferences. Those data 
related to: a) relevance of different treatment endpoints from the patient’s perspec-
tive in oncology, hepatitis C, diabetes, or HIV infection; b) patient preference for a 
specific drug administration route (e.g. oral vs. injections), administration system (e.g. 
different inhalation systems), or administration frequency; c) patient preference for 
therapy duration or type of therapy. In none of the assessment reports did the evaluat-
ing committee specifically address the evidence presented on patient preferences. A 
comment on patient preference data was stated in one assessment report only (for 
aclidiniumbromid). ConClusions: About a quarter of value dossiers referred to data 
on patient preference. Surprisingly, it appears that the evidence on patient preference 
has not been considered in the AMNOG benefit assessments despite the fact that 
benefit to the patient is the central criterion of the AMNOG early benefit assessment.
PHP214
raPId relatIve effectIveness assessment of PHarmaceutIcals: 
transferaBIlIty and comPleteness of InformatIon derIved from 
gloBal value dossIers to comPlete a eunetHta suBmIssIon
Neeser K.1, Lister J.1, Stanisic S.2, Stengel C.1, Mueller E.1
1LASER ANALYTICA, Loerrach, Germany, 2LASER ANALYTICA, Milano, Italy
objeCtives: EUnetHTA is currently evaluating the applicability of the Core Model® 
for Rapid Relative Effectiveness Assessment of Pharmaceuticals of selected drugs for 
which a market authorization is intended between 2013 and 2015. A global value 
dossier (GVD) represents an important tool for pharmaceutical manufacturer (PM) 
to consolidate information on considered disease, its management and treat-
ment, epidemiology, as well as health economic outcomes. The current study 
is intended to quantify the information that may be transferable from a well 
prepared, comprehensive GVD to EUnetHTA submission via gap analysis. The 
EUnetHTA submission comprises of 4 modules: 1. Description of the health prob-
lem; 2. Technical characteristics of technology and appropriate comparator(s); 3. 
Clinical effectiveness, and 4. Safety of the new drug. Methods: A GVD, developed 
for a pharmaceutical product, was used as data source to evaluate the feasibility 
to address all questions in the four EUnetHTA modules. Results: In modules 1 
and 2 about 60% of data that are required to complete the EUnetHTA submission 
are missing from the GVD. Most of this information (e.g. implementation of the 
new drug, current use of the drug) may be easily obtained from other documents 
held by PM. In modules 3 and 4 about 70% of queries cannot be answered without 
additional assessments (e.g. complementary evidence synthesis, study quality 
assessments), systematic searches (e.g. on-going unpublished studies) and addi-
tional sources. ConClusions: A GVD can be a useful pool of knowledge for a 
new drug in a specific indication. Despite this large body of evidence, a consider-
able part of the information that is required for a EUnetHTA submission may be 
missing from GVDs and needs to be derived from existing clinical study reports, 
extensive systematic literature searches and additional evaluations. Applying of 
validated and systematic methods during the GVD development process may 
reduce additional work for assessment reports.
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objeCtives: In light of growing interest in Health Technology Assessment 
(HTA) related outcomes being incorporated into post-authorisation studies (PAS) 
of medicines, an HTA Working Group of the European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance (ENCePP) has been established. 
The Working Group’s current focus is on establishing baseline data to shape 
the network’s activities in meeting emerging demands for evidence generation 
in PAS. Therefore, an exploratory survey was undertaken to map current capa-
bilities related to research that supports HTA and to identify relevant training 
needs. Methods: An online survey was developed and piloted within the HTA 
Working Group prior to distribution to over 200 researchers on the ENCePP mailing 
list. The items in the survey were both qualitative and quantitative. Data will be 
analysed using simple descriptive statistics and thematic analysis. Results: The 
survey is ongoing and will close in July 2014. Preliminary results indicate that (50%) 
of those sampled had conducted studies involving patient reported outcomes 
(PROs) including quality of life data. The most frequently used data collection 
tools were: paper (80%), handheld devices (50%), interactive voice (30%) and web-
based (30%). Clinical outcomes were the most frequent primary study endpoints 
(100%), although at least some data on PROs and cost outcomes were included in 
86% and 71% of studies, respectively. The most common design was primary data 
collection prospective cohort studies. ENCePP guidelines were the most frequently 
referenced followed by ISPOR and ISPE methodological good practice guidelines. 
Full data analyses will be available in September 2014. ConClusions: The find-
ings of the ENCePP-HTA WG survey provide baseline data on ENCePP expertise 
and resources in research supporting HTA that are of interest to regulatory and 
HTA stakeholders across Europe.
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objeCtives: The National Institute of Health and Care Excellence (NICE) is a body 
that has gathered worldwide respect for its fully comprehensive clinical and economic 
review of pharmaceutical agents. However, it has been criticized for taking too long 
to conduct assessments and, as a consequence of this, only being able to appraise a 
subset of all new agents coming to market. Other Health technology Asessment (HTA) 
bodies achieve a much higher output of treatment appraisals with a much shorter 
turnaround time (e.g. in 2013 NICE appraised 27 drugs compared to 57 by the National 
Centre for Pharmacoeconomics (NCPE), Ireland). Methods: A thematic analysis of 
the appraisal processes of the NCPE was conducted to determine if any key criteria 
could be extrapolated that could potentially increase the speed and output of the NICE 
appraisal process. Results: One particularly interesting aspect of the NCPE system 
was revealed – a 2 to 4 week rapid preliminary review that all drugs must undergo to 
determine the necessity of a full pharmaco-economic assessment (PEA). Full PEAs are 
reserved for products with high cost, significant budget impact, and/or questionable 
value for money. This enables products that are cheaper and at least as efficacious as 
the relevant comparator to gain rapid market access. It also enables the NCPE to focus 
their time and resources on the products that will have a substantial/questionable 
clinical and/or economic impact. ConClusions: Adoption of such a systematic rapid 
review procedure into the NICE appraisal process with reimbursement conditional on 
NICE approval could similarly enable a better focussing of NICE resources to where 
it is most impactful. This could also incentivise pharmaceutical companies to drop 
their prices to gain rapid market access rather than going through the expensive and 
time consuming procedure of a full NICE submission.
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objeCtives: Many medical devices offer improvements over current care that 
may be difficult to assess using standard methods of benefit such as the quality-
adjusted life-year (QALY). The objective of this research was to identify whether 
these benefits could be measured and valued by alternative approaches, such as 
contingent valuation (willingness-to-pay) or conjoint analysis (discrete choice experi-
ments). Methods: We undertook a systematic review of the literature from 1996 to 
2013 to identify empirical studies of the benefits of medical devices using the follow-
ing methodologies: willingness-to-pay (WTP), discrete choice experiments (DCEs), 
multi-criteria decision analysis (MCDAs) and subjective well-being (SWB). We recorded 
the number and category of individuals surveyed, the attributes explored and the 
key findings of each study. Results: The search resulted in 2772 hits, of which 2016 
were considered not relevant and 76 were duplicates. On further examination, 47 of 
the remaining 680 papers were found not to meet our inclusion criteria, 240 were 
methodological papers and 363 involved non-device technologies. This left 30 relevant 
empirical studies, of which 18 were WTP and 12 DCEs. The types of devices studied 
included hearing aids, hip and knee implants and colostomy bags. Comfort, conveni-
ence or ease of use was the most common attribute explored other than effectiveness 
and quality of the device. Where both were studied, patient preferences sometimes 
differed from those of physicians. ConClusions: This research demonstrates that it 
is feasible to measure and value the benefits of devices using alternative approaches 
to QALYs, but that the literature is quite small as compared with that for non-device 
technologies. This is surprising given the often-repeated claim that devices have 
benefits that are difficult to assess using standard methods. Whilst the studies dem-
onstrate the relative importance of each attribute, thought is required on how to 
incorporate these estimates into comparative cost-effectiveness studies.
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